Cencora (COR) is lower today as investors react to a fresh share-supply catalyst tied to its longtime strategic shareholder. Walgreens Boots Alliance disclosed it early-settled certain prepaid variable share forward transactions and sold related shares of Cencora, a setup that can translate into immediate market supply and renewed expectations for additional monetization of remaining holdings. (s23.q4cdn.com)

Even without a change in Cencora’s fundamentals, large-holder monetizations can pressure the stock because they increase trading supply and can reset near-term sentiment around the shareholder overhang. The drop looks flow-driven rather than operational: the most recent major company update was its fiscal 2026 first-quarter results and guidance refresh earlier in the quarter, not new day-of news from Cencora itself. (investor.cencora.com)

Traders will focus on whether Walgreens signals additional transactions that could bring more COR shares to market, and whether Cencora’s capital-allocation posture changes (including potential buyback pacing) as it integrates OneOncology and updates its FY2026 outlook through the year. Any further details on the size/timing of the Walgreens-related share sales could be a key near-term driver for COR’s tape. (s23.q4cdn.com)